ChemoThermia was founded in 2010 by Prof. Bulent Berkarda, Assoc. Prof. Mehmet Salih İyikesici, two of the most experienced medical oncologists in Turkey, and Dr. Abdul Kadir Slocum, a leading proponent of integrative cancer care, in order to deliver world class cancer treatment using the latest integrative approaches.

At ChemoThermia, we are committed to expanding the paradigms for cancer treatment with the ultimate goal of creating a holistic treatment model which supports the patient whilst attacking the cancer, as opposed to attacking the cancer by attacking the patient. Our approach is grounded in the scientific understanding of the role of cellular metabolism in health – an overlooked area which is attracting increasing attention across the medical spectrum.

The fundamental premise of our approach is that cellular metabolism has a foundational role in all aspects of our health due to its role in regulating energy transference and balance throughout the body. Supporting and balancing this system against both the debilitations of cancer and of its treatment can increase the patient’s resilience to both, giving them more time to fight the disease.

Every individual’s metabolism is unique and we therefore believe that an integrative, holistic approach to cancer treatment must be equally personalised in order to have the highest chance of success.

At ChemoThermia, we put these theories into practice and are committed to ensuring every single patient gets the best that cutting-edge integrative oncology has to offer. We have one of the highest success rates of any cancer clinic in the world and publish our results in leading peer reviewed journals so that the wider medical community can share our experience and integrate the lessons from our approach in their own practice.

We develop personalised protocols for each of our patients, integrating both genetic and metabolic approaches together with supportive strategies to maximise the efficacy and reduce the side effects of conventional treatment by targeting the metabolic vulnerabilities present in cancer cells.

The therapies we use include:

All patients’ progress is tracked with PET-CT scans as well as MRIs and other imaging techniques as necessary, with scans carried out using the latest equipment at internationally recognised imaging centers and reviewed by leading experts in the field. Since our foundation we have published a number of papers sharing details of our treatment and results and continue to actively research and integrate the latest developments in the field.

While the vast majority of our patients are stage IV we welcome enquiries at all stages after diagnosis and for all types of cancer.

Meet our team